Not yet peer reviewed you say? Well, that doesn't matter today....It only mattered when Trump wanted to promote Hydroxy to help...But, you couldn't abide that then could you?COVID research: a year of scientific milestones
Nature waded through the literature on the coronavirus — and summarized key papers as they appeared.www.nature.com
15 April — Common asthma medicine could shave days off COVID illness
A clinical trial in more than 4,600 people at risk of serious COVID-19 found that an inhalable asthma medication shortened the duration of disease symptoms by about 3 days.
The asthma drug budesonide is an inexpensive and widely available inhalable steroid. Christopher Butler and Richard Hobbs at the University of Oxford, UK, and their colleagues tested budesonide in people who had COVID-19 symptoms but were not hospitalized (PRINCIPLE Collaborative Group et al. Preprint at medRxiv Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial; 2021).
Participants either were over the age of 65 or were more than 50 years old and had conditions that increased their risk of COVID-19 complications. Participants were randomly assigned to either receive the drug or serve in a control group, but none took a placebo. Both participants and investigators knew who had received the drug.
Those who took budesonide twice daily for two weeks reported that their COVID-19 symptoms ended three days earlier than those who did not use the steroid. The results have not yet been peer reviewed.